Japan-based Otsuka Pharmaceutical has signed a deal with Danish pharmaceutical company Lundbeck for the development of psychiatric and neuroscience drugs.
The deal covers five medications, including two of Otsuka’s late-stage drugs – a depot formulation of schizophrenia drug Abilify and OPC-34712, currently in Phase III trials for the treatment of schizophrenia and major depressive disorder.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As per the terms of the agreement, Otsuka will receive an upfront payment of $200m from Lundbeck, followed by up to $1.4bn in development and regulatory milestones.
Lundbeck will receive 50% and 20% of European and US sales respectively for the Abilify depot formulation, as well as 50% of sales in Europe and Canada and 45% of US sales of OPC-34712.
